Skip to main content

ASLAN Pharmaceuticals Limited (ASLN)

NASDAQ: ASLN · IEX Real-Time Price · USD
3.27
+0.02 (0.62%)
After-hours:Sep 24, 2021 7:54 PM EDT
3.25
0.01 (0.31%)
At close: Sep 24, 4:00 PM
Market Cap226.26M
Revenue (ttm)189,710
Net Income (ttm)-22.07M
Shares Out69.62M
EPS (ttm)-0.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,135,594
Open3.26
Previous Close3.24
Day's Range3.12 - 3.36
52-Week Range1.42 - 6.75
Beta2.37
AnalystsBuy
Price Target5.50 (+69.2%)
Est. Earnings DateNov 5, 2021

About ASLN

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for mark...

IndustryBiotechnology
IPO DateMay 4, 2018
CEOCarl Firth
Employees18
Stock ExchangeNASDAQ
Ticker SymbolASLN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ASLN stock is "Buy." The 12-month stock price forecast is 5.50, which is an increase of 69.23% from the latest price.

Price Target
$5.50
(69.23% upside)
Analyst Consensus: Buy

News

ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual Global Healthcare Conference

MENLO PARK, Calif., and SINGAPORE, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments...

4 days ago - GlobeNewsWire

ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Expert Dr Lawrence E...

MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments...

5 days ago - GlobeNewsWire

Implied Volatility Surging for ASLAN Pharmaceuticals (ASLN) Stock Options

Investors need to pay close attention to ASLAN Pharmaceuticals (ASLN) stock based on the movements in the options market lately.

1 week ago - Zacks Investment Research

ASLAN Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

SINGAPORE, Aug. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives ...

1 month ago - GlobeNewsWire

ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development

ASLAN Pharmaceuticals (NASDAQ: ASLN) has closed a secured loan facility provided by K2 HealthVentures (K2HV).  Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured debt ...

2 months ago - Benzinga

ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures

Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003 Funds extend expected cash runway through late 2023 and enable advancement of clinical program...

2 months ago - GlobeNewsWire

Why ASLAN Pharmaceuticals Blasted Higher on Friday

An analyst initiates the company's stock with a very bullish note.

2 months ago - The Motley Fool

New Strong Sell Stocks for June 8th

ASLN, CANG, ESLT, GCI, and KRYS have been added to the Zacks Rank #5 (Strong Sell) List on June 8, 2021.

Other symbols:CANGESLTGCIKRYS
3 months ago - Zacks Investment Research

New Strong Sell Stocks for June 4th

ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.

Other symbols:BLRXFLXNICMBMRNS
3 months ago - Zacks Investment Research

ASLAN Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

- Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021  - Phase 2b clinical trial for ASLAN004 expected to initi...

4 months ago - GlobeNewsWire

ASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative Dermatology

- ASLAN will give a poster presentation of new data from its Single Ascending Dose (SAD) study of ASLAN004, during the virtual event on 6 May, 2021

4 months ago - GlobeNewsWire

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021 Next data readout for ASLAN004 in the treatment of patients...

5 months ago - GlobeNewsWire

What Makes ASLAN Pharmaceuticals Ltd. (ASLN) a New Buy Stock

ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6 months ago - Zacks Investment Research

ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares

SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives ...

6 months ago - GlobeNewsWire

ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives ...

6 months ago - GlobeNewsWire

ASLN Stock: Why Aslan Pharmaceuticals Is Up 20% Today

Investors in ASLN stock seem to like the company's initial clinical test results, as well as the company's overall market position. The post ASLN Stock: Why Aslan Pharmaceuticals Is Up 20% Today appeare...

6 months ago - InvestorPlace

Aslan Pharmaceuticals Shares Are Trading Higher On Positive ASLAN004 Data In Atopic Dermatitis

Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) announces positive interim unblinded data from its ongoing Phase 1 study evaluating ASLAN004 to treat moderate to severe atopic dermatitis (AD). Subcutaneous del...

6 months ago - Benzinga

ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic De...

- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90

6 months ago - GlobeNewsWire

ASLAN Pharmaceuticals Announces $18 Million Private Placement

SINGAPORE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of...

7 months ago - GlobeNewsWire

ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director

SINGAPORE, Feb. 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of...

7 months ago - GlobeNewsWire

New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting...

— New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors

8 months ago - GlobeNewsWire

ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial

- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels

8 months ago - GlobeNewsWire

ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Buy: Rationale Behind the Upgrade

ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

9 months ago - Zacks Investment Research

ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference

SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of...

10 months ago - GlobeNewsWire

ASLAN Pharmaceuticals (ASLN) Sees Hammer Chart Pattern: Time to Buy?

ASLAN Pharmaceuticals (ASLN) has been struggling lately, but the selling pressure may be coming to an end soon.

10 months ago - Zacks Investment Research